Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus cisplatin vs cisplatin in triple-negative metastatic breast cancer
2006-005000-13Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in triple-negative breast cancer (TNBC) comparing Cetuximab + cisplatin with Cisplatin alone (2 arms). Primary endpoint: Best overall response. Started Feb 2007; status: completed.
02
Drugs
cetuximabcisplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2006-005000-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005000-13.